RecruitingNCT07235501
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
Sponsor
City of Hope Medical Center
Enrollment
75 participants
Start Date
Oct 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the factors that contribute to chronic graft-versus-host disease, which is a complication that can occur after allogeneic hematopoietic cell transplantation.
Eligibility
Min Age: 7 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Non-Interventional Study for people with graft-versus-host disease, hematopoietic and lymphatic system neoplasm, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 7 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07235501
Related Trials
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
NCT06126276188 locations
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT075350081 location
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT060134231 location
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT050923731 location
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT0569149123 locations